nach oben

Erschienen in:

06.06.2020 | Clinical Study

Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial

verfasst von: Bolin Liu, Shujuan Liu, Yuan Wang, Dan Lu, Lei Chen, Tao Zheng, Tao Ma, Yufu Zhang, Guodong Gao, Yan Qu, Shiming He

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

A novel neurosurgical enhanced recovery after surgery (ERAS) program shortens postoperative hospital stay and accelerates functional recovery in elective craniotomy patients. There is a need to evaluate the impact of ERAS program on patients’ health-related quality of life (HRQOL).

Methods

In a single-center randomized controlled trial, patients were randomized 1:1 to receive perioperative ERAS or conventional care. As a secondary outcome, HRQOL was measured with the EORTC QLQ-C30/BN20 prior to randomization (baseline), at discharge, and at 3- and 6-month follow-up.

Results

A total of 65 patients (ERAS: n = 36, conventional care: n = 29) with pathologically confirmed glioma (WHO grade 2–4) were included in the analysis. Progression-free survival at 6 months and HRQOL at baseline were similar between the two groups. Changes of scores did not vary significantly over time, but differed significantly between intervention groups. A clinically relevant better QoL (at 3-month follow-up), physical functioning (at 6-month follow-up) and role functioning (at discharge) was observed in patients in the ERAS group. Symptom scores of constipation (at discharge), motor dysfunction (at discharge, 3- and 6-month follow-up), drowsiness (at 3- and 6-month follow-up), weakness of legs (at 3-month follow-up), and nausea/vomiting (at discharge and 6-month follow-up) were significantly lower in the ERAS group.

Conclusions

The neurosurgical ERAS program seems to improve functioning and symptoms scores in glioma patients within 6-month follow-up compared with conventional care. The intervention has a significant main effect HRQOL changes without significant interaction with time. Future well-powered multicenter studies are warranted to confirm this result and address long-term benefits.

This study has been registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn/showproj.aspx?proj=16480) with registration number ChiCTR-INR-16009662.

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, Pekmezci M, Schwartzbaum JA, Turner MC, Walsh KM, Wrensch MR, Barnholtz-Sloan JS (2014) The epidemiology of glioma in adults: a "state of the science" review. Neuro-oncology 16(7):896–913. https://doi.org/10.1093/neuonc/nou087CrossRefPubMedPubMedCentral

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306–2316. https://doi.org/10.1001/jama.2017.18718CrossRefPubMedPubMedCentral

Weller M (2011) Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials. Neuro-oncology 13(6):565. https://doi.org/10.1093/neuonc/nor065CrossRefPubMedPubMedCentral

Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A, Zvi Ram on behalf of the EFTI (2017) Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 135(3):545–552. https://doi.org/10.1007/s11060-017-2601-yCrossRef

Greer NL, Gunnar WP, Dahm P, Lee AE, MacDonald R, Shaukat A, Sultan S, Wilt TJ (2018) Enhanced recovery protocols for adults undergoing colorectal surgery: a systematic review and meta-analysis. Dis Colon Rectum 61(9):1108–1118. https://doi.org/10.1097/DCR.0000000000001160CrossRefPubMed

Jones EL, Wainwright TW, Foster JD, Smith JR, Middleton RG, Francis NK (2014) A systematic review of patient reported outcomes and patient experience in enhanced recovery after orthopaedic surgery. Ann R Coll Surg Engl 96(2):89–94. https://doi.org/10.1308/003588414X13824511649571CrossRefPubMedPubMedCentral

Kehlet H, Wilmore DW (2008) Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg 248(2):189–198. https://doi.org/10.1097/SLA.0b013e31817f2c1aCrossRefPubMed

Ljungqvist O, Scott M, Fearon KC (2017) Enhanced recovery after surgery: a review. JAMA Surg 152(3):292–298. https://doi.org/10.1001/jamasurg.2016.4952CrossRefPubMed

Wang Y, Liu B, Zhao T, Zhao B, Yu D, Jiang X, Ye L, Zhao L, Lv W, Zhang Y, Zheng T, Xue Y, Chen L, Sankey E, Chen L, Wu Y, Li M, Ma L, Li Z, Li R, Li J, Yan J, Wang S, Zhao H, Sun X, Gao G, Qu Y, He S (2018) Safety and efficacy of a novel neurosurgical enhanced recovery after surgery protocol for elective craniotomy: a prospective randomized controlled trial. J Neurosurg. https://doi.org/10.3171/2018.1.JNS171552CrossRefPubMedPubMedCentral

10.

Liu B, Liu S, Wang Y, Zhao B, Zhao T, Zhao L, Lv W, Zhang Y, Zheng T, Xue Y, Chen L, Chen L, Wu Y, Gao G, Qu Y, He S (2019) Neurosurgical enhanced recovery after surgery (ERAS) programme for elective craniotomies: are patients satisfied with their experiences? A quantitative and qualitative analysis. BMJ Open 9(11):e028706. https://doi.org/10.1136/bmjopen-2018-028706CrossRefPubMedPubMedCentral

11.

Ma R, Livermore LJ, Plaha P (2016) Fast track recovery program after endoscopic and awake intraparenchymal brain tumor surgery. World Neurosurg 93:246–252. https://doi.org/10.1016/j.wneu.2016.06.015CrossRefPubMed

12.

Quadros DG, Neville IS, Urena FM, Solla DJF, Paiva WS, Teixeira M (2019) Safety and costs analysis of a fast-track algorithm for early hospital discharge after brain tumor surgery. Neurosurgery. https://doi.org/10.1093/neuros/nyz310_432CrossRef

13.

China MAotNHCo (2019) Chinese criteria for diagnosis and treatment of glioma (2018 edition). Chin J Neurosurg 31:557–577

14.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (10):987–996. doi: 10.1056/NEJMoa043330

15.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMed

16.

Cheng JX, Liu BL, Zhang X, Zhang YQ, Lin W, Wang R, Zhang YQ, Zhang HY, Xie L, Huo JL (2011) The validation of the standard Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) in pre-operative patients with brain tumor in China. BMC Med Res Methodol 11:56. https://doi.org/10.1186/1471-2288-11-56CrossRefPubMedPubMedCentral

17.

Zhang K, Tian J, He Z, Sun W, Pekbay B, Lin Y, Wu D, Zhang J, Chen P, Guo H, Wan Y, Wang M, Yang S, Zheng J, Zhang L (2018) Validation of the Chinese version of EORTC QLQ-BN20 for patients with brain cancer. Eur J Cancer Care 27(2):e12832. https://doi.org/10.1111/ecc.12832CrossRef

18.

Fayers PM, Aronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual. European Organisation for Research and Treatment of Cancer, Brussels

19.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139–144. https://doi.org/10.1200/JCO.1998.16.1.139CrossRefPubMed

20.

Liu B, Wang Y, Liu S, Zhao T, Zhao B, Jiang X, Ye L, Zhao L, Lv W, Zhang Y, Zheng T, Xue Y, Chen L, Chen L, Wu Y, Li Z, Yan J, Wang S, Sun X, Gao G, Qu Y, He S (2018) A randomized controlled study of preoperative oral carbohydrate loading versus fasting in patients undergoing elective craniotomy. Clin Nutr. https://doi.org/10.1016/j.clnu.2018.11.008CrossRefPubMedPubMedCentral

21.

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R (2018) Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol 4(4):495–504. https://doi.org/10.1001/jamaoncol.2017.5082CrossRefPubMedPubMedCentral

22.

Yavas C, Zorlu F, Ozyigit G, Gurkaynak M, Yavas G, Yuce D, Cengiz M, Yildiz F, Akyol F (2012) Health-related quality of life in high-grade glioma patients: a prospective single-center study. Support Care Cancer 20(10):2315–2325. https://doi.org/10.1007/s00520-011-1340-4CrossRefPubMed

23.

Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R (2003) Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol 63(2):179–186. https://doi.org/10.1023/a:1023900802254CrossRefPubMed

24.

Cheng JX, Liu BL, Zhang X, Lin W, Zhang YQ, Liu WP, Zhang JN, Lin H, Wang R, Yin H (2010) Health-related quality of life in glioma patients in China. BMC Cancer 10:305. https://doi.org/10.1186/1471-2407-10-305CrossRefPubMedPubMedCentral

25.

Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, Kakde A (2009) Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol 95(3):413–419. https://doi.org/10.1007/s11060-009-9939-8CrossRefPubMed

Titel: Impact of neurosurgical enhanced recovery after surgery (ERAS) program on health-related quality of life in glioma patients: a secondary analysis of a randomized controlled trial
verfasst von: Bolin Liu
Shujuan Liu
Yuan Wang
Dan Lu
Lei Chen
Tao Zheng
Tao Ma
Yufu Zhang
Guodong Gao
Yan Qu
Shiming He
Publikationsdatum: 06.06.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03548-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

PARP inhibition suppresses the emergence of temozolomide resistance in a model system

Fluorescein-mediated sonodynamic therapy in a rat glioma model

Long-term survival outcomes of pineal region gliomas

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer

Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients

A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma